Literature DB >> 19760606

Claspin inhibition leads to fragile site expression.

Maria Luisa Focarelli1, Samuela Soza, Linda Mannini, Marianna Paulis, Alessandra Montecucco, Antonio Musio.   

Abstract

Fragile sites are hot spots for sister chromatid exchanges, translocations, deletions, complex rearrangements, and gene amplification. It has been hypothesized that rearrangements at fragile sites derive from unreplicated regions resulting from stalled forks that escape the ATR replication checkpoint. In the present study, we investigated the role of the Claspin (CLSPN) gene, which codes for an adaptor protein in the ATR pathway, during DNA replication stress in human cells. We show that the inhibition of the CLSPN gene leads to both genome instability and fragile site expression. Following aphidicolin treatment, we found a transient increase of Claspin synthesis due to its requirement to checkpoint activation. However, Claspin synthesis decreased after a prolonged aphidicolin treatment. We propose that CLSPN modulation, following an extreme replication block, allows rare cells to escape checkpoint mechanisms and enter mitosis with a defect in genome assembly. Our observations provide the basis for a better understanding of cell cycle checkpoints deregulation in cancer. (c) 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19760606     DOI: 10.1002/gcc.20710

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  16 in total

1.  The conserved C terminus of Claspin interacts with Rad9 and promotes rapid activation of Chk1.

Authors:  Shizhou Liu; Na Song; Lee Zou
Journal:  Cell Cycle       Date:  2012-07-15       Impact factor: 4.534

2.  IKK and NF-kappaB-mediated regulation of Claspin impacts on ATR checkpoint function.

Authors:  Niall Steven Kenneth; Sharon Mudie; Sonia Rocha
Journal:  EMBO J       Date:  2010-07-23       Impact factor: 11.598

3.  Population-scale analysis of human microsatellites reveals novel sources of exonic variation.

Authors:  L J McIver; J F McCormick; A Martin; J W Fondon; H R Garner
Journal:  Gene       Date:  2012-12-26       Impact factor: 3.688

4.  Separation of intra-S checkpoint protein contributions to DNA replication fork protection and genomic stability in normal human fibroblasts.

Authors:  Stephanie L Smith-Roe; Shivani S Patel; Yingchun Zhou; Dennis A Simpson; Shangbang Rao; Joseph G Ibrahim; Marila Cordeiro-Stone; William K Kaufmann
Journal:  Cell Cycle       Date:  2012-01-15       Impact factor: 4.534

5.  Claspin as a biomarker of human papillomavirus-related high grade lesions of uterine cervix.

Authors:  Maria Benevolo; Antonio Musio; Amina Vocaturo; Maria Gabriella Donà; Francesca Rollo; Irene Terrenato; Mariantonia Carosi; Edoardo Pescarmona; Giuseppe Vocaturo; Marcella Mottolese
Journal:  J Transl Med       Date:  2012-06-25       Impact factor: 5.531

Review 6.  Replication fork recovery and regulation of common fragile sites stability.

Authors:  Annapaola Franchitto; Pietro Pichierri
Journal:  Cell Mol Life Sci       Date:  2014-09-13       Impact factor: 9.261

Review 7.  Interplay between genetic and epigenetic factors governs common fragile site instability in cancer.

Authors:  Efrat Ozeri-Galai; Michal Tur-Sinai; Assaf C Bester; Batsheva Kerem
Journal:  Cell Mol Life Sci       Date:  2014-10-09       Impact factor: 9.261

Review 8.  Fragile sites in cancer: more than meets the eye.

Authors:  Thomas W Glover; Thomas E Wilson; Martin F Arlt
Journal:  Nat Rev Cancer       Date:  2017-07-25       Impact factor: 60.716

9.  Characterization of functional domains in human Claspin.

Authors:  Ozdemirhan Serçin; Michael G Kemp
Journal:  Cell Cycle       Date:  2011-05-15       Impact factor: 4.534

10.  Genome rearrangements caused by depletion of essential DNA replication proteins in Saccharomyces cerevisiae.

Authors:  Edith Cheng; Jessica A Vaisica; Jiongwen Ou; Anastasia Baryshnikova; Yong Lu; Frederick P Roth; Grant W Brown
Journal:  Genetics       Date:  2012-06-05       Impact factor: 4.562

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.